SNOA announces departure of EVP/COO Bruce Thornton on Oct 18, 2025

Rhea-AI Filing Summary

Sonoma Pharmaceuticals reported a leadership change. The company terminated Bruce Thornton as Executive Vice President and Chief Operating Officer, effective October 18, 2025. He also left any other positions at the company and its subsidiaries.

According to the disclosure, Mr. Thornton will receive only compensation and benefits earned through October 18, 2025. The filing did not state any additional payments. Sonoma’s common stock trades on Nasdaq under the symbol SNOA.

Insights

Corporate governance analyst

Executive change disclosed; compensation limited to amounts earned.

Sonoma Pharmaceuticals announced the departure of its EVP/COO, Bruce Thornton, effective October 18, 2025. Executive transitions can affect operations, but the excerpt provides no details on interim coverage or succession.

The company stated he will receive only amounts earned through October 18, 2025, indicating no additional severance in this disclosure. The business impact depends on leadership continuity and operational handoffs, which are not detailed in the excerpt.

false 0001367083 0001367083 2025-10-18 2025-10-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 18, 2025

SONOMA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-33216		68-0423298
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

5445 Conestoga Court, Suite 150

Boulder, CO 80301

(Address of principal executive offices)

(Zip Code)

(800) 759-9305

(Registrant’s telephone number, including area code)

Not applicable.

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock	SNOA	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 18, 2025, Bruce Thornton was terminated as an employee and Executive Vice President and Chief Operating Officer of the Company, and from any other position at the Company or any of its subsidiaries to which he has been appointed. Mr. Thorton was terminated for cause in accordance with the terms of his employment agreement and will not receive any salary or benefits from the Company except those earned through October 18, 2025.

This report contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company’s future activities, or future events or conditions. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in the Company’s Annual Report on Form 10-K and in other documents that the Company files from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this report, except as required by law.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SONOMA PHARMACEUTICALS, INC.
Date: October 23, 2025	By:	/s/ Amy Trombly
	Name: Title:	Amy Trombly Chief Executive Officer

3

FAQ

What executive change did Sonoma Pharmaceuticals (SNOA) disclose?

The company terminated Bruce Thornton as Executive Vice President and Chief Operating Officer, effective October 18, 2025.

When was Bruce Thornton’s termination effective at Sonoma Pharmaceuticals (SNOA)?

It was effective on October 18, 2025.

What compensation will Bruce Thornton receive from Sonoma Pharmaceuticals (SNOA)?

He will receive only salary and benefits earned through October 18, 2025.

Did Sonoma Pharmaceuticals (SNOA) disclose severance for Bruce Thornton?

The disclosure states he will receive only amounts earned through October 18, 2025.

What is Sonoma Pharmaceuticals’ (SNOA) stock listing?

Common stock trades on Nasdaq under the symbol SNOA.